Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101)

Abstract

Major lung resection followed by postoperative cisplatin and etoposide is feasible, with a favorable survival profile. Because nodal metastasis appears to be a major prognostic factor, preoperative evaluation of nodal status remains a major concern.

Role of adjuvant therapy in early-stage small-cell lung cancer: comment on a population-based cohort study of patients with early-stage small-cell lung cancer

“…Only four prospective studies have evaluated the outcomes of patients receiving adjuvant therapy following surgery for SCLC. Table 1 summarizes these four studies (3)(4)(5)(6), which are singlearm, prospective phase II trials, including various chemotherapy regimens, with or without irradiation. These adjuvant treatments were generally well tolerated with acceptable levels of toxicity.…”

Clinical Results of Stereotactic Body Radiotherapy for Stage I Small Cell Lung Cancer: A Single Institutional Experience

“…The 5-year overall survival rates after surgery for Stage I SCLC have been reported as approximately 50-70 % [14][15][16][17]. Although it is difficult to compare these results directly, mainly because of the difference between the pathological stage and clinical stage, the 3-year survival rate in our study using SBRT compared favorably to those of surgical series previously listed.…”

Surgery in Small-Cell Lung Cancer: Past, Present and Future

“…For stage I addition of surgery to conventional treatments (chemo-radiation) improved 5-year survival rate from 11.3% to 44.9%, so Authors concluded that patients with resectable disease in stage I should be referred to surgery [Rostad, 2004]. The same conclusion is reported by Leo and Pastorino in their review [Leo & Pastorino, 2003] High 5 years survival rate was reported also by Tsuchiya in a retrospective series of patients treated with a similar protocol [Tsuchiya, 2005]. Interestingly, Authors reported only 10% of local failure after surgery, which is lower than commonly reported after chemo-radiation therapies alone.…”